Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "S. de Bellis", 70013 Castellana Grotte, Italy.
Center of Nutrition for the Research and the Care of Obesity and Metabolic Diseases, National Institute of Gastroenterology IRCCS "Saverio de Bellis", 70013 Castellana Grotte, Italy.
Nutrients. 2023 May 30;15(11):2561. doi: 10.3390/nu15112561.
The very-low-calorie ketogenic diet (VLCKD) is effective and safe for obese individuals, but limited information exists on its impact on the intestinal barrier. This study analyzed the effects of 8 weeks of VLCKD on 24 obese patients (11M/13F). Carbohydrate intake was fixed at 20-50 g/day, while protein and lipid intake varied from 1-1.4 g/kg of ideal body weight and 15-30 g per day, respectively. Daily calorie intake was below 800 kcal. The lactulose-mannitol absorption test assessed small intestinal permeability. Multiple markers, such as serum and fecal zonulin, fatty acid-binding protein, diamine oxidase concentrations, urinary dysbiosis markers (indican and skatole), and circulating lipopolysaccharide levels, were analyzed. Inflammation markers (serum interleukin 6, 8, 10, and tumor necrosis factor-α concentrations) were also evaluated. The results showed significant reductions in weight, BMI, and waist circumference post-diet. However, the lactulose-mannitol ratio increased by 76.5%, and a significant increase in dysbiosis markers at the end of the diet occurred. This trend was particularly evident in a subgroup of patients. Despite initial benefits, the VLCKD might negatively affect the intestinal barrier function in obese patients, potentially worsening their compromised intestinal balance.
极低卡路里生酮饮食(VLCKD)对肥胖个体有效且安全,但关于其对肠道屏障的影响的信息有限。本研究分析了 8 周 VLCKD 对 24 名肥胖患者(11M/13F)的影响。碳水化合物摄入量固定在 20-50 克/天,而蛋白质和脂肪摄入量分别为 1-1.4 克/公斤理想体重和每天 15-30 克。每日热量摄入低于 800 卡路里。乳果糖-甘露醇吸收试验评估了小肠通透性。分析了多种标志物,如血清和粪便肠通透素、脂肪酸结合蛋白、二胺氧化酶浓度、尿微生态失调标志物(吲哚和粪臭素)和循环脂多糖水平。还评估了炎症标志物(血清白细胞介素 6、8、10 和肿瘤坏死因子-α浓度)。结果表明,饮食后体重、BMI 和腰围显著减轻。然而,乳果糖-甘露醇比值增加了 76.5%,饮食结束时微生态失调标志物显著增加。这种趋势在患者亚组中尤为明显。尽管最初有获益,但 VLCKD 可能会对肥胖患者的肠道屏障功能产生负面影响,可能会使他们受损的肠道平衡恶化。